Abstract: The present invention concerns implantable ocular devices for the sustained release of medication to the eye, and methods for manufacturing and using such devices. In one embodiment, the present invention provides a device comprising: (a) a body comprising a matrix of a prostaglandin and a silicone; (b) a parylene coating on the outer surface of the body; and (c) one or more pores extending from the outer surface of the parylene coating to the outer surface of the body.

Abstract: The present invention is directed to an ophthalmic peri-corneal drug delivery device. The device includes a core of matrix material and therapeutic agent and a coating over the core. One or more opening[s] extend through the coating to provide for release of the drug to the eye. Moreover, the device is designed to lay atop the external surface of the eye.

Abstract: The present invention concerns implantable ocular devices for the sustained release of medication to the eye, and methods for manufacturing and using such devices. In one embodiment, the present invention provides a device comprising: (a) a body comprising a matrix of a prostaglandin and a silicone; (b) a parylene coating on the outer surface of the body; and (c) one or more pores extending from the outer surface of the parylene coating to the outer surface of the body.

Abstract: A system having an injection cartridge and plunger tip which are adapted to be used on commercially available intraocular lens injection systems. The injection cartridge is shorter and smaller in diameter than typical intraocular lens injection cartridge. The plunger tip has an extended, small diameter section sized to slide easily within a round bore in the cartridge. A stop prevents the plunger tip from being expelled from the cartridge. The entire system, including drug delivery device, may be packaged as a single, terminally sterilized unit, does not require manipulation of the drug delivery device and may be used with a wide variety of drug delivery formulations.